Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-25-033493
Filing Date
2025-04-21
Accepted
2025-04-21 08:32:15
Documents
3
Period of Report
2025-04-21

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea023888801-6k_enlivex.htm 6-K 8672
2 PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON APRIL 21, 2025. ea023888801ex99-1_enlivex.htm EX-99.1 11573
3 GRAPHIC ex99-1_001.jpg GRAPHIC 2560
  Complete submission text file 0001213900-25-033493.txt   25195
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36578 | Film No.: 25851365
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)